Responsible for Late Stage Portfolio Committee (LSPC) operations, investment decision analysis and late-stage portfolio performance management to enable robust governance decision-making for late-stage pipeline investments to optimize and speed delivery of new medicines to patients.Late-stage governance: In partnership with executive R&D and commercial leaders, develop the late-stage governance agenda and lead effective, focused meetings. Manage timelines for future investment decisions, data readouts and strategic consultations. Robust governance decision-making: Provide portfolio context and analyses – based on time, cost, value and risk - for all governance decisions to ensure optimal decision making. Consult with global project teams to assist in preparation for investment decisions and ensure successful governance interactions. Performance Management: Prepare project and portfolio data to measure pipeline performance against goals. Portfolio Management, Planning & Reporting: Maintain a detailed understanding of the shape and drivers of the R&D portfolio through proactive involvement with key stakeholders in R&D and commercial leadership, project management and leadership, finance, forecasting and competitive intelligence. Asses project and pipeline delivery in context of external and internal performance benchmarks.Transparent Governance Processes: Manage all “Drug Project Operating Model” guidance processes and documents to provide clear paths for global project teams to advance projects through development.

Designed and teach “BIOT-801: Portfolio Strategy & Drug Project Management” to graduate students in GU’s biomedical program and business school.

Collaborate with scientific and commercial executives to develop and implement therapeutic area strategies and optimize portfolio decision-making for a differentiated and competitive pipeline.• Drive development of the global therapeutic area strategy across development and commercialization. Lead multiple, matrixed stakeholders to build end-to-end strategies, identify opportunities for new investment or externalization, prioritize and advance a global, competitive portfolio.• General manager for the Therapeutic Area Leadership Governance Team. Set governance agendas, drive rigorous decision-making and prioritization, provide analysis and manage risk. • Restructured, trained and lead senior project managers who drive global drug development teams. • Oversee a team developing “Project Management University”, an innovative learning and development initiative that trains and builds project management capability across multiple functions in AstraZeneca's late stage development organization including Clinical Operations, Regulatory, Bioinformation & Statistics, Biopharmaceutical Development & Technology, China Drug Development and Japan Drug Development.

Collaborate with senior scientific and commercial leaders to implement therapeutic area strategy by providing targeted recommendations and analyses that inform portfolio optimization, prioritization and decision-making for a differentiated and competitive pipeline.• Drive development of the global ING therapeutic area strategy across development and commercialization functions. Through this process, lead multiple, diverse stakeholders to build disease area sub-strategies, identify new investment opportunities, select future value drivers and identify projects for externalization.• Helped build a new governance structure to drive late-stage development and commercialization decisions for portfolio investments. Serve as general manager for three Therapeutic Area Leadership Team that drive governance and late-stage development and commercialization decision-making for portfolio investments.• Provide inputs for regular portfolio reviews to AZ’s Senior Executive Team and stakeholders throughout the organization. Oversee team that is accountable for metrics/performance reporting, driving quality portfolio data with project teams and employing decision-making tools and analytics to solve complex issues.

• As chief of staff, managed Portfolio Strategy & Management team operations including implementing change management initiatives, preparing executive presentations, setting leadership team agendas and goals, driving team performance, managing a multi-million dollar budget and ensuring cross-team collaboration.• Led development of quarterly portfolio reviews to executive leaders (CEO, CFO, EVPs) that measure portfolio progress, deliver insights and provide forward recommendations for pipeline optimization.• Spearheaded global, enterprise-wide change initiatives across three science units to streamline business processes. Revamped the portfolio update operating model resulting in improved quality, simpler processes and increased speed in delivering portfolio analyses to executive leaders.

Lead a team that implements external relations and collaboration strategies for MedImmune executives to advance the company’s reputation as a global biotechnology leader, position the company on critical business/government/civic issues and foster scientific/business partnerships. Manage internal executive engagement strategies to shape a productive, entrepreneurial culture and encourage two-way communication among 2,500 globally based employees. MedImmune is the worldwide biologics research and development arm of AstraZeneca ($25.7 billion in 2013 revenue).Key Accomplishments:• Implemented the InvestMaryland Program and raised $84M in venture capital funding to build start-up companies in life sciences, information technology and green technology sectors, as advisor to the Chair of the Maryland Venture Fund Authority.• Manage board of directors for the Hong Kong-based WuXi AppTec/MedImmune Joint Venture, a novel biologics company serving the Chinese market. • Achieved an $11M, 5-year collaboration with Johns Hopkins University and the University of Maryland System to advance scientific R&D and exchange talent and scientific/business expertise.• Principal advisor to company President as a Board Director to the Biotechnology Industry Organization (BIO) and Chairman of the Regulatory Environment Committee. • Strategically secured public speeches, board appointments and engagement opportunities for MedImmune executives at key partnership organizations such as BIO; BioHealth Innovation, Inc.; Maryland Research BioPark Corporation; University of Maryland-Baltimore Foundation; Association for Women in Science; Healthcare Businesswomen’s Association; International Society of Professional Engineers; and the Tech Council of Maryland.• Established and oversaw an enterprise-wide management structure to provide business communications/reports from MedImmune’s president to the parent company’s CEO, Executive Team and Board of Directors.

Built a new function that led all federal, state and international public policy and strategic initiatives with a goal of maximizing access and utilization of the company’s biopharmaceutical products and positively impacting corporate reputation.

Lobbyist of all state legislative and regulatory initiatives in a Midwest region and manager of a team of lobbyists. Helped create a new government affairs team.

Lobbyist for corporate, pharmaceuticals and diagnostics divisions in Midwest region. Generated more than $50 million in sales for company products in diverse therapeutic areas including HIV/AIDS, weight loss, hepatitis C, oncology, transplant, antivirals and antibiotics.

Led policy development and lobbying of health care and social services issues. Governor's liaison to Departments of Medical Services (Medicaid), Public Health, Mental Health and Aging.